l-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-β peptide in rats

European Journal of Pharmacology

Volumn 621, Issue 1-3, 2009, Pages 38-45

  Peng, Ying ^a,c   Xing, Changhong ^b   Xu, Shaofeng ^a   Lemere, Cynthia A ^c   Chen, Guiquan ^c   Liu, Bin ^a,c   Wang, Ling ^a   Feng, Yipu ^a   Wang, Xiaoliang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid ; l 3 n butylphthalide (L NBP); Learning and memory deficits; Tau protein phosphorylation

Indexed keywords

3 BUTYLPHTHALIDE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CASPASE 3; CHOLINE ACETYLTRANSFERASE; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; MALONALDEHYDE; TAU PROTEIN; VEGETABLE OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME ACTIVATION; ENZYME ACTIVITY; HIPPOCAMPUS; INHIBITION KINETICS; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; WORKING MEMORY;

AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; BENZOFURANS; CEREBRAL VENTRICLES; COGNITION DISORDERS; INFUSION PUMPS; LEARNING; MALE; MEMORY; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RATS; RATS, WISTAR; TAU PROTEINS;

EID: 70349617912     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.036     Document Type: Article

References (56)

1. Anderson A.J., Su J.H., and Cotman C.W. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 16 (1996) 1710-1719
2. Braak H., and Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
3. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005) 675-688
4. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., and Jucker M. Neuron loss in APP transgenic mice. Nature 395 (1998) 755-756
5. Chang Q., and Wang X.L. Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta. Pharmacol. Sin. 24 (2003) 796-804
6. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., and Morris R.G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 (2000) 975-979
7. Chen Z., Duan R.S., Lepecheur M., Paly E., London J., and Zhu J. SOD-1 inhibits FAS expression in cortex of APP transgenic mice. Apoptosis 10 (2005) 499-502
8. Crack P.J., Cimdins K., Ali U., Hertzog P.J., and Iannello R.C. Lack of glutathione peroxidase-1 exacerbates Abeta-mediated neurotoxicity in cortical neurons. J. Neural. Transm. 113 (2006) 645-657
9. Dayan A.D. Quantitative histological studies on the aged human brain. II. Senile plaques and neurofibrillary tangles in senile dementia (with an appendix on their occurrence in cases of carcinoma). Acta. Neuropathol. (Berl.) 16 (1970) 95-102
10. Dong G.X., and Feng Y.P. Effects of NBP on ATPase and anti-oxidant enzymes activities and lipid peroxidation in transient focal cerebral ischemic rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24 (2002) 93-97
11. Fifre A., Sponne I., Koziel V., Kriem B., Yen Potin F.T., Bihain B.E., Olivier J.L., Oster T., and Pillot T. Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. J. Biol. Chem. 281 (2006) 229-240
12. Gervais F.G., Xu D., Robertson G.S., Vaillancourt J.P., Zhu Y., Huang J., LeBlanc A., Smith D., Rigby M., Shearman M.S., Clarke E.E., Zheng H., Van Der Ploeg L.H., Ruffolo S.C., Thornberry N.A., Xanthoudakis S., Zamboni R.J., Roy S., and Nicholson D.W. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97 (1999) 395-406
13. Grimes C.A., and Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65 (2001) 391-426
14. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., and Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U S A 83 (1986) 4913-4917
15. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
16. Hardy J.A., and Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992) 184-185
17. Iqbal K., and Grundke-Iqbal I. Developing pharmacological therapies for Alzheimer disease. Cell Mol. Life Sci. 64 (2007) 2234-2244
18. Johnson G.V., and Hartigan J.A. Tau protein in normal and Alzheimer's disease brain: an update. J. Alzheimers Dis. 1 (1999) 329-351
19. Kar S., and Quirion R. Amyloid beta peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. Prog. Brain Res. 145 (2004) 261-274
20. Kobayashi K., Nakano H., Hayashi M., Shimazaki M., Fukutani Y., Sasaki K., Sugimori K., and Koshino Y. Association of phosphorylation site of tau protein with neuronal apoptosis in Alzheimer's disease. J. Neurol. Sci. 208 (2003) 17-24
21. Koistinaho M., Ort M., Cimadevilla J.M., Vondrous R., Cordell B., Koistinaho J., Bures J., and Higgins L.S. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. U S A 98 (2001) 14675-14680
22. Kowall N.W., Beal M.F., Busciglio J., Duffy L.K., and Yankner B.A. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc. Natl. Acad. Sci. U S A 88 (1991) 7247-7251
23. Lee C.L., Kuo T.F., Wang J.J., and Pan T.M. Red mold rice ameliorates impairment of memory and learning ability in intracerebroventricular amyloid beta-infused rat by repressing amyloid beta accumulation. J. Neurosci. Res. 85 (2007) 3171-3182
24. Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., and McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293 (2001) 1487-1491
25. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
26. Malaplate-Armand C., Florent-Bechard S., Youssef I., Koziel V., Sponne I., Kriem B., Leininger-Muller B., Olivier J.L., Oster T., and Pillot T. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 23 (2006) 178-189
27. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
28. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11 (1984) 47-60
29. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
30. Nitta A., Fukuta T., Hasegawa T., and Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn. J. Pharmacol. 73 (1997) 51-57
31. Nitta A., Itoh A., Hasegawa T., and Nabeshima T. beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170 (1994) 63-66
32. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
33. Olariu A., Yamada K., Mamiya T., Hefco V., and Nabeshima T. Memory impairment induced by chronic intracerebroventricular infusion of beta-amyloid (1-40) involves downregulation of protein kinase C. Brain Res. 957 (2002) 278-286
34. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., and Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58 (1999) 1010-1019
35. Peng Y., Xing C.H., Lemere C.A., Chen G.Q., Xu S.F., Wang L., Feng Y.P., and Wang X.L. L-3-n-butylphthalide Ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci. Lett. 434 (2008) 224-229
36. Peng Y., Xu S., Chen G., Wang L., Feng Y., and Wang X. l-3-n-Butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J. Pharmacol. Exp. Ther. 321 (2007) 902-910
37. Peng Y., Xu S., Wang L., Feng Y., and Wang X. Effect of L-3-n-butylphthalide on cerebral infarct volume in the transient cerebral ischemia rats. Chin. J. New Drug 14 (2005) 420-423
38. Peng Y., Zeng X., Feng Y., and Wang X. Antiplatelet and antithrombotic activity of L-3-n-butylphthalide in rats. J. Cardiovasc. Pharmacol. 43 (2004) 876-881
39. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., and Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U S A 99 (2002) 6364-6369
40. Reddy P.H. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J. Neurochem. 96 (2006) 1-13
41. Sakakibara Y., Mitha A.P., Ogilvy C.S., and Maynard K.I. Post-treatment with nicotinamide (vitamin B(3)) reduces the infarct volume following permanent focal cerebral ischemia in female Sprague-Dawley and Wistar rats. Neurosci. Lett. 281 (2000) 111-114
42. Spillantini M.G., and Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21 (1998) 428-433
43. Stephan A., and Phillips A.G. A case for a non-transgenic animal model of Alzheimer's disease. Genes Brain Behav. 4 (2005) 157-172
44. Stephanichev M., Zdobnova I., Zarubenko I., Lazareva N., and Gulyaeva N. Studies of the effects of central administration of β-amyloid peptide (25-35):pathomorphological changes in the hippocampus and impairment of spatial memory. Neurosci Behav Physiol. 36 (2006) 101-106
45. Vieira M.N., Forny-Germano L., Saraiva L.M., Sebollela A., Martinez A.M., Houzel J.C., De Felice F.G., and Ferreira S.T. Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration. J. Neurochem. 103 (2007) 736-748
46. Waite J., Cole G.M., Frautschy S.A., Connor D.J., and Thal L.J. Solvent effects on beta protein toxicity in vivo. Neurobiol. Aging 13 (1992) 595-599
47. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
48. Wang R., Zhang H.Y., and Tang X.C. Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur. J. Pharmacol. 421 (2001) 149-156
49. Xiong J., and Feng Y. The protective effect of butylphthalide against mitochondrial injury during cerebral ischemia. Yao Xue Xue Bao 35 (2000) 408-412
50. Xu H., and Feng Y. Effects of d-3-n-butylphthalide (NBP) on pial arterioles in focal cerebral ischemia rats. Acta. Pharm. Sin. 34 (1999) 172-175
51. Xu H.L., and Feng Y.P. Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats. Acta. Pharmacol. Sin. 21 (2000) 433-438
52. Xu H.L., and Feng Y.P. Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats. Acta. Pharmacol. Sin. 36 (2001) 329-333
53. Yamada K., Tanaka T., Mamiya T., Shiotani T., Kameyama T., and Nabeshima T. Improvement by nefiracetam of beta-amyloid-(1-42)-induced learning and memory impairments in rats. Br. J. Pharmacol. 126 (1999) 235-244
54. Yamaguchi Y., Miyashita H., Tsunekawa H., Mouri A., Kim H.C., Saito K., Matsuno T., Kawashima S., and Nabeshima T. Effects of a novel cognitive enhancer, spiro[imidazo-[1, 2-a]pyridine-3, 2-indan]-2(3H)-one (ZSET1446), on learning impairments induced by amyloid-beta1-40 in the rat. J. Pharmacol. Exp. Ther. 317 (2006) 1079-1087
55. Yan C.H., Feng Y.P., and Zhang J.T. Effects of dl-3-n-butylphthalide on regional cerebral blood flow in right middle cerebral artery occlusion rats. Zhongguo Yao Li Xue Bao 19 (1998) 117-120
56. Youdim M.B., and Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26 (2005) 27-35